TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05586360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40mg taken orally daily for 8 weeks
Study: NCT05894005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality (IVR)
Description: * Group A IVR: Students will be first taken to the anesthesia lounge. Here the students will receive IVR instructions on how to navigate the route (i.e. they will watch a 360-degree video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of the route~* Group B 2D video: Students will be first taken to the anesthesia lounge. Students will receive 2D video instruction on how to navigate the route by watching a normal 2D video using a desktop computer screen. Then the students will be assessed with an observed walkthrough of the route.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality (IVR)
Description: * Group A IVR: Students will be first taken to the anesthesia lounge. Here the students will receive IVR instructions on how to navigate the route (i.e. they will watch a 360-degree video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of the route~* Group B 2D video: Students will be first taken to the anesthesia lounge. Students will receive 2D video instruction on how to navigate the route by watching a normal 2D video using a desktop computer screen. Then the students will be assessed with an observed walkthrough of the route.
Study: NCT05952037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered orally as a tablet.
Study: NCT06331728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGNX001
Description: IGNX001 given as a single subcutaneous dose on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to IGNX001 given as a single subcutaneous dose on Day 1.
Study: NCT04551131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given orally (PO) or per nasogastric tube (NGT) twice a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given orally (PO) or per nasogastric tube (NGT) twice a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given intravenously (IV) or orally (PO) twice a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given intravenously (IV) or orally (PO) twice a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given intravenously (IV) once a week for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given intravenously (IV) once a week for 8 weeks
Study: NCT05009069

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluorouracil
Description: Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
Study: NCT06601712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence support strategy A
Description: Community health worker (CHW) support through monthly home visits to remind the caregiver to administrate the PDMC drugs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence support strategy B
Description: SMS/phone reminders from the qualified community health officers (ASCQ) to the community health workers (CHW) to administrate the PDMC drugs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No reminders
Study: NCT05726903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-subQ Provera Injectable Product
Description: SC Injection at Home
Study: NCT04086485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DOTATATE
Description: Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DOTATATE
Description: Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
Study: NCT04920253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Device Debridement
Description: debritom+ water jet debridement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOC Debridement
Description: Sharp Scalpel
Study: NCT03958019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESTORE II Program
Description: Detailed in arm description
Study: NCT04086485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ga dotatate scanning
Description: Ga68-DOTATATE PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ga dotatate scanning
Description: Ga68-DOTATATE PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
Study: NCT06658184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep restriction and stimulus control
Description: Sleep restriction: a) Reduce bedtime to match actual sleep time, but ≥4.5 hours, and adjust bedtime according to sleep efficiency; b) Avoid daytime naps and maintain a regular wake-up time.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sleep hygiene education
Description: Sleep hygiene education:~1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.
Study: NCT04086485

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET scanning
Description: F18-FDG PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET scanning
Description: F18-FDG PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acid infusion
Description: Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acid infusion
Description: Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.
Study: NCT06662344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Oral-esophageal Tube Feeding
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
Study: NCT05211635

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: One capsule daily for 84 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for 84 days
Study: NCT04181333

Intervention type: DRUG
Intervention: TRASTUZUMAB BS
Description: Regimen A or regimen B is used for HER2-overexpressing breast cancer.~RegimenB is used for HER2-overexpressing unresectable advanced or recurrent gastric cancer in combination with other anti tumor agent(s).~Regimen A: The recommended dose for trastuzumab (genetical recombination) \[Trastuzumab Biosimilar 3\] in adult patients is 4 mg/kg (weight) at initial dose and 2 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every week.~Regimen B: The recommended dose for trastuzumab (genetical recombination) \[Trastuzumab Biosimilar 3\] in adult patients is 8 mg/kg (weight) at initial dose and 6 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every 3 weeks.~If the initial dose is well tolerated, the dosing time after the second dose can be shortened up to 30 minutes.
Study: NCT05561842

Intervention type: PROCEDURE
Intervention: mHealth US-breast biopsy
Description: During this study, women will undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
Study: NCT05682378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran sodium 300mg (equivalent to 284mg inclisiran\*) in 1.5mL solution administered subcutaneously in pre-filled syringe
Study: NCT05971147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Participants in this group will receive 5g fish oil with high EPA and DHA content per day
Study: NCT06123650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitve transcranial magnetic stimulation
Description: The Magstim Rapid2 magnetic stimulator system (Model P/N 3576-23-09, Magstim Company, Whitland, UK) was used to deliver rTMS electrical currents via a figure of 8 coil applied to the scalp against the targeted contralesional motor  Hot spot , at a depth of approximately 1 cm . The inhibitory rTMS will be applied to the intact cerebral hemisphere at 1 Hz with a train of 1200 for 5 consecutive days.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham transcranial magnetic stimulation
Description: Repetitive TMS via a sham Magstim coil (identical appearance and noise, but no active stimulation). Identical stimulation schedules as patients in study group.
Study: NCT05465629

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME Precision Nutrition Program
Description: Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME-designed condition-based supplements
Description: Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Study: NCT05980949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: KarXT 20/2 mg TID (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
Study: NCT05140200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3511294
Description: GSK3511294 will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3511294
Description: GSK3511294 will be administered.
Study: NCT06660394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP352
Description: LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered with matching placebo orally or through G-tube/ PEG tube
Study: NCT06607276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab and capecitabine
Description: Adebrelimab: 1200mg, IV, q3w for one year; capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
Study: NCT06395090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab/Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vibostolimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab
Description: IV infusion
Study: NCT06610838

Intervention type: OTHER
Intervention: Health Assessments
Description: Participants will complete the blood tests, questionnaires, cardiovascular tests, and pulmonary test at visits 1, 2, and 4. Non-Contrast Chest CT and cardiopulmonary treadmill (VO2 max) stress tests will occur at visits 1 and 4. Visit 3 will not include cardiovascular and pulmonary tests.

Intervention type: OTHER
Intervention: Health Assessments
Description: Participants will complete the blood tests, questionnaires, cardiovascular tests, and pulmonary test at visits 1, 2, and 4. Non-Contrast Chest CT and cardiopulmonary treadmill (VO2 max) stress tests will occur at visits 1 and 4. Visit 3 will not include cardiovascular and pulmonary tests.
Study: NCT06660810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec (HSV-1 \[strain JS1\]/ICP34.5-/ICP47-/hGM-CSF) is an oncolytic immunotherapy, formerly known as OncoVEXGM-CSF, an immune-enhanced, oncolytic herpes simplex virus type 1 (HSV-1)~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiation
Description: Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given.~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care
Study: NCT06662344

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study: NCT05125016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4336
Description: Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4336
Description: Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion
Study: NCT06411041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT) and yoga
Description: The experimental group participants will be instructed to perform the practice session four days a week. The four days per week practice times (PFMT 15 minutes/day; yoga 40 minutes/day.) will result in weekly practice times for pelvic floor muscle training (PFMT) of 60 minutes and for yoga of ≥150 minutes.
Study: NCT06151834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KeriFuse implant implantation
Description: The surgery is an arthrodesis of finger or thumb (for patients with finger osteoarthritis) and involves implanting the KeriFuse implant.
Study: NCT05125016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4336
Description: Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered concomitantly every 3 weeks (Q3W) by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5678
Description: Administered concomitantly QW by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Administered once by IV infusion as prophylaxis prior to REGN4336 IV
Study: NCT06662344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study: NCT06658392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive tasks
Description: no intervention in a medical sense, only observing changes of BOLD signal during different experimental conditions in cognitive tasks (arithmetic, attention, inhibition)
Study: NCT06658769

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theta Burst Stimulation
Description: Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation (NIBS) technique that involves modulating brain excitability and activity, which can increase or decrease depending on the parameters used. Theta Burst Stimulation (TBS) mimics the brain's natural firing patterns more closely and may have greater effects on cognitive performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theta Burst Stimulation
Description: Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation (NIBS) technique that involves modulating brain excitability and activity, which can increase or decrease depending on the parameters used. Theta Burst Stimulation (TBS) mimics the brain's natural firing patterns more closely and may have greater effects on cognitive performance.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Theta Burst Stimulation Sham
Description: Theta Burst Stimulation simulated with 90º coil orientation with lower part external to the scalp.